CRH Medical Corporation (NASDAQ:CRHM) has been assigned a consensus broker rating score of 1.20 (Strong Buy) from the five analysts that provide coverage for the company, Zacks Investment Research reports. One analyst has rated the stock with a buy recommendation and four have assigned a strong buy recommendation to the company. CRH Medical’s rating score has improved by 9.8% from 90 days ago as a result of a number of analysts’ upgrades and downgrades.
Brokers have set a twelve-month consensus price objective of $4.93 for the company, according to Zacks. Zacks has also given CRH Medical an industry rank of 76 out of 256 based on the ratings given to its competitors.
Separately, Bloom Burton upgraded CRH Medical from an “accumulate” rating to a “buy” rating in a research note on Thursday, August 1st.
About CRH Medical
CRH Medical Corporation provides various products and services to gastroenterologists for the treatment of gastrointestinal diseases in the United States, Canada, and internationally. It offers CRH O'Regan system, a single use, disposable, and hemorrhoid banding technology for treating various grades of hemorrhoid.
Recommended Story: Short Selling Stocks and Day Traders
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for CRH Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRH Medical and related companies with MarketBeat.com's FREE daily email newsletter.